Cellectar Biosciences Nets Patent
The U.S. Patent and Trademark Office has awarded Cellectar Biosciences a patent (No. P150207US03) that covers a method of use for CLR 131 in multiple myeloma, the company announced today….
Tag Archives: Cellectar Biosciences
Cellectar Receives Orphan Drug Designation
Cellectar Biosciences has been granted orphan drug designation for its therapeutic, CLR 131, by the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development for the treatment of neuroblastoma,…
Cellectar Earns Allowance for Patent
The U.S. Patent and Trademark Office awarded Cellectar Biosciences a notice of allowance for a patent covering the use of CLR 131 in multiple myeloma (MM), the company announced today. “This patent…
Cellectar, Pierre Fabre Extend Relationship
Cellectar Biosciences has extended its collaboration with Pierre Fabre, a French pharmaceutical company, the company announced today. “The extension of our research agreement with Pierre Fabre allows us to further…
Cellectar, Onconova Therapeutics Collaborate
Cellectar Biosciences announced today it has entered into a strategic collaboration with Onconova Therapeutics, a biopharmaceutical company, to develop new phospholipid drug conjugates (PDC). According to a release, the Newtown,…
Cellectar’s Platform Shows Therapeutic Potential
Cellectar Biosciences‘ Phospholipid Drug Conjugate (PDC) research program has generated numerous PDC molecules that show “significant” improved pharmacologic activity, the company announced today. According to a release, Cellectar’s research demonstrates that…
Cellectar Provides Myeloma Study Update
Cellectar Biosciences’ CLR 131 has achieved an overall survival of greater than 22 months in advanced multiple myeloma patients, the company announced today. “We continue to make meaningful progress on…
Cellectar Announces Swiss Collaboration
Cellectar Biosciences announced today that it will collaborate with Avicenna Oncology, a clinical stage biotechnology company based in Switzerland, to develop new phospholipid drug conjugates for solid tumors. According to…
Cellectar Adds Two to Board
Cellectar Biosciences added Douglas Swirsky and Frederick Driscoll to its board of directors, the company announced recently. Swirsky is the president and CEO of GenVec and has worked at Stifel Nicolaus…
Cellectar to Begin Phase II Trial
Cellectar Biosciences announced today its initiation of a Phase II clinical study of CLR 131 in patients with multiple myeloma and other hemotologic malignancies. According to a release, the study…
